BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21184913)

  • 1. Positron emission tomography for benign and malignant disease.
    Visioni A; Kim J
    Surg Clin North Am; 2011 Feb; 91(1):249-66. PubMed ID: 21184913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT in oncology: for which tumours is it the reference standard?
    Collins CD
    Cancer Imaging; 2007 Oct; 7 Spec No A(Special issue A):S77-87. PubMed ID: 17921085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET in oncology: will it replace the other modalities?
    Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
    Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effective PET investigations in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
    Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of contrast-enhanced computed tomography and positron emission tomography with 18-FDG in identifying malignant solitary pulmonary nodules.
    Dabrowska M; Krenke R; Korczynski P; Maskey-Warzechowska M; Zukowska M; Kunikowska J; Orłowski T; Chazan R
    Medicine (Baltimore); 2015 Apr; 94(15):e666. PubMed ID: 25881842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Positron emission tomography (PET) in clinical oncology. Part II].
    Cabrera Villegas A; Gámez Cenzano C; Martín Urreta JC
    Rev Esp Med Nucl; 2002 Apr; 21(2):131-47; quiz 149-51. PubMed ID: 11879626
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
    Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
    Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-fluorine fluorodeoxyglucose positron emission tomography with computerized tomography versus computerized tomography alone for the management of solitary lung nodules with diameters inferior to 1.5 cm.
    Divisi D; Di Tommaso S; Di Leonardo G; Brianzoni E; De Vico A; Crisci R
    Thorac Cardiovasc Surg; 2010 Oct; 58(7):422-6. PubMed ID: 20922626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
    Bryant AS; Cerfolio RJ
    Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
    Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
    AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effective PET scans in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
    Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
    Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
    Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using neighborhood gray tone difference matrix texture features on dual time point PET/CT images to differentiate malignant from benign FDG-avid solitary pulmonary nodules.
    Chen S; Harmon S; Perk T; Li X; Chen M; Li Y; Jeraj R
    Cancer Imaging; 2019 Aug; 19(1):56. PubMed ID: 31420006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
    Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
    Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A proposal for the rational use of the PET in oncology].
    Borrego Dorado I; Vázquez Albertino R
    Rev Esp Med Nucl; 2002 May; 21(3):163-73. PubMed ID: 12206749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging in lung cancer: positron emission tomography scan.
    Vansteenkiste JF
    Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.